Sector revisions Northwest Biotherapeutics, Inc. Börse Stuttgart

Stocks

Market Closed - Börse Stuttgart Other stock markets 15:56:12 2026-07-14 EDT			5-day change	1st Jan Change
0.1500 ^EUR	-6.25%		-6.25%	-27.18%

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	WUXI APPTEC CO., LTD.							17
	ARGENX SE							15
	INSMED INCORPORATED							21
	BIONTECH SE							20
	WUXI BIOLOGICS (CAYMAN) INC.							22
	GENMAB A/S							15
	PHARMAESSENTIA CORPORATION							7
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							17
	EXELIXIS, INC.							16
	MADRIGAL PHARMACEUTICALS, INC.							14
	SUMMIT THERAPEUTICS INC.							13
	CYTOKINETICS, INCORPORATED							20
	AKESO, INC.							20
	ARROWHEAD PHARMACEUTICALS, INC.							11
	NUVALENT, INC.							16
	REMEGEN CO., LTD.							14
	CRINETICS PHARMACEUTICALS, INC.							10
	IMMUNITYBIO, INC.							3
	Average							15
	Weighted average by Cap.							16